Loading…
Reported covered position: Staff Assistant/Legislative Correspondent, Representative John Culberson; Legislative Assistant/Senior Legislative Assistant, Representative Bill Shuster; Legislative Director/Deputy Chief of Staff, Representative David McKinley
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · third_quarter · 3A
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · second_quarter · 2A
Source: Senate LDA
| ORCHARD THERAPEUTICS NORTH AMERICA |
| 8 |
| 2024–2026 |
| REPUBLIC SERVICES, INC. | 8 | 2025–2026 |
| ROCKET LIMITED PARTNERSHIP (F/K/A RKT HOLDINGS, LLC) | 8 | 2020–2026 |
| SHIELD AI | 8 | 2025–2026 |
| VAPOR TECHNOLOGY ASSOCIATION | 8 | 2025–2026 |
| WALGREEN COMPANY | 8 | 2025–2026 |
| AMERICAN EXPLORATION & PRODUCTION COUNCIL | 7 | 2025–2026 |
| CONSUMER TECHNOLOGY ASSOCIATION | 7 | 2025–2026 |
| GLAS INC. | 7 | 2025–2026 |
| GOODRX | 7 | 2025–2026 |
| HUMANA, INC. | 7 | 2025–2026 |
| BRIGHTHOUSE SERVICES, LLC | 6 | 2025–2026 |
| CIGAR ASSOCIATION OF AMERICA | 6 | 2025 |
| NATIONAL INSURANCE CRIME BUREAU | 6 | 2025–2026 |
| PNC FINANCIAL INC. | 6 | 2025–2026 |
| COHESITY, INC. | 5 | 2025–2026 |
| LKQ CORPORATION | 5 | 2025–2026 |
| NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION | 5 | 2025–2026 |
| NATIONAL FOOTBALL LEAGUE | 5 | 2025–2026 |
| WALMART INC | 5 | 2025–2026 |
| BROWN-FORMAN CORPORATION | 4 | 2026 |
| DOORDASH | 4 | 2026 |
| EXPEDIA GROUP | 4 | 2025 |
| JAPAN TOBACCO INTERNATIONAL USA INC. | 4 | 2026 |
| NOVO NORDISK, INC. | 4 | 2026 |
| RECYCLING LEADERSHIP COUNCIL | 4 | 2026 |
| SWISHER INTERNATIONAL INC. | 4 | 2026 |
| CONSUMER BRANDS ASSOCIATION | 3 | 2026 |
| FORIS DAX, INC. D/B/A CRYPTO.COM | 3 | 2026 |
| Fresenius Kabi | 3 | 2025 |
| GOOGLE CLIENT SERVICES LLC | 3 | 2026 |
| META PLATFORMS INC (FORMERLY FACEBOOK INC AND VARIOUS SUBSIDIARIES) | 3 | 2026 |
| MONDELEZ INTERNATIONAL | 3 | 2026 |
| SANDOZ INC. | 3 | 2026 |
| CTIA - THE WIRELESSS ASSOCIATION | 2 | 2026 |
| HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION | 1 | 2025 |
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
HR 4105 (Veterans Energy Transition Act)
HR 4105 (Veterans Energy Transition Act)
Limiting Liability for Critical Infrastructure Manufacturers Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
H.R. 4194 Limiting Liability for Critical Infrastructure Manufacturers Act (Wildfire liability protections for manufacturers of critical grid components)
Limiting Liability for Critical Infrastructure Manufacturers Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
H.R. 4194 Limiting Liability for Critical Infrastructure Manufacturers Act (Wildfire liability protections for manufacturers of critical grid components)
High-Capacity Grid Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
Electrification policy; energy efficiency; grid and cyber security; transmissions; permitting reform; HR. 6633 High Capacity Grid Act alongside REWIRE Act
High-Capacity Grid Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
Electrification policy; energy efficiency; grid and cyber security; transmissions; permitting reform; HR. 6633 High Capacity Grid Act alongside REWIRE Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Electrification policy; energy efficiency; grid and cyber security; transmissions; permitting reform; S. 3947 REWIRE Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Limiting Liability for Critical Infrastructure Manufacturers Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
H.R. 4194 Limiting Liability for Critical Infrastructure Manufacturers Act (Wildfire liability protections for manufacturers of critical grid components)
Limiting Liability for Critical Infrastructure Manufacturers Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
H.R. 4194 Limiting Liability for Critical Infrastructure Manufacturers Act (Wildfire liability protections for manufacturers of critical grid components)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Science and Transparency Over Politics Act
Client: ROCKET LIMITED PARTNERSHIP F/K/A RKT HOLDINGS, LLC · Firm: S-3 GROUP
Mortgage servicing and data privacy issues; general FHA, FHFA, VA, USDA issues; oversight of federal housing policy; S.4638 National Defense Authorization Act for Fiscal Year 2025; General tax reform; qualified office conversion tax credit
Science and Transparency Over Politics Act
Client: ROCKET LIMITED PARTNERSHIP F/K/A RKT HOLDINGS, LLC · Firm: S-3 GROUP
Mortgage servicing and data privacy issues; general FHA, FHFA, VA, USDA issues; oversight of federal housing policy; S.4638 National Defense Authorization Act for Fiscal Year 2025; General tax reform; qualified office conversion tax credit
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · first_quarter · 1A
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RECYCLING LEADERSHIP COUNCIL via S-3 GROUP
2026 · third_quarter · Q3
Issues pertaining to advanced recycling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to tariffs and importation of counterfeit drugs.
Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.
Issues related to compounding and counterfeit drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JAPAN TOBACCO INTERNATIONAL USA INC. via S-3 GROUP
2026 · third_quarter · Q3
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
BROWN-FORMAN CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to corporate tax policy, tariffs, including duty drawbacks
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SWISHER INTERNATIONAL INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues pertaining to tobacco and nicotine; monitoring activity at FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to auto parts market
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to privacy, data security, and funding
Issues related to privacy and data security
Issues related to privacy, data security, and funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding lower prescription drug prices for patients
Issues regarding lower prescription drug prices for patients
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Product applications related to the FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · third_quarter · Q3
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous platforms for border and national security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MONDELEZ INTERNATIONAL via S-3 GROUP
2026 · third_quarter · Q3
Issues related to food and nutrition policy
Issues related to food and nutrition policy
Issues related to trade, taxes, and tariffs
ABBOTT LABORATORIES via S-3 GROUP
2026 · third_quarter · Q3
Issues related to infant formula
Proposals to reform domestic and international tax structures
Equitable Access to Community Pharmacist Services Act
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · third_quarter · Q3
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · third_quarter · Q3
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · third_quarter · Q3
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FORIS DAX, INC. D/B/A CRYPTO.COM via S-3 GROUP
2026 · third_quarter · 3T
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via S-3 GROUP
2026 · third_quarter · Q3
Issues related to funding for newborn screenings for metachromatic leukodystrophy
Issues related to funding for newborn screenings for metachromatic leukodystrophy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN EXPLORATION & PRODUCTION COUNCIL via S-3 GROUP
2026 · third_quarter · Q3
Monitor issues and legislation to support the resonsible production of American oil and gas
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCKET LIMITED PARTNERSHIP F/K/A RKT HOLDINGS, LLC via S-3 GROUP
2026 · third_quarter · Q3
Mortgage servicing and data privacy issues; general FHA, FHFA, VA, USDA issues; oversight of federal housing policy
General tax reform; qualified office conversion tax credit
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANDOZ INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues and legislative proposals on biosimilars and generics medicines, including but not limited to generics and biosimilar sustainability, pharmaceutical supply chain security, drug shortages, interchangeability, patent litigation, and PBM reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to policy matters impacting labor, independent workers, gig economy, consumer issues and food, restaurant, small businesses
Issues pertaining to policy matters impacting labor, independent workers, gig economy, consumer issues and food, restaurant, small businesses
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
General educational meetings on policy issues impacting tech platforms
Monitor issues related to consumer data privacy, and children's privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
S. 448/H.R. 4128 (CIRCUIT Act), and future opportunities (Recon 3.0), focusing on expansion of the 45X tax credit
Section 232 tariffs, including measures affecting steel, aluminum, semiconductors, and critical minerals, as well as actions related to reciprocal tariffs; advanced NEMA's tariff incentive proposal to accelerate energy and domestic manufacturing priorities.
Electrification policy; energy efficiency; grid and cyber security; transmissions; permitting reform; HR. 6633 High Capacity Grid Act alongside REWIRE Act
2026 · third_quarter · Q3
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
Issued related to PL 119-21: One Big Beautiful Bill Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FORIS DAX, INC. D/B/A CRYPTO.COM via S-3 GROUP
2026 · third_quarter · Q3
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
META PLATFORMS, INC. (FORMERLY FACEBOOK, INC. AND VARIOUS SUBSIDIARIES) via S-3 GROUP
2026 · third_quarter · Q3
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER BRANDS ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Consumer packaged goods and sustainability and recyclability of packaged goods
Issues related to the food and beverage industries
Issues related to the food and beverage industries
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities; issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE CLIENT SERVICES, LLC via S-3 GROUP
2026 · third_quarter · Q3
Issues related to human trafficking efforts and criminal justice reform
Issues related to intellectual property enforcement
Issues related to competition in online services
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · 2A
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · 2A
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RECYCLING LEADERSHIP COUNCIL via S-3 GROUP
2026 · second_quarter · Q2
Issues pertaining to advanced recycling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to tariffs and importation of counterfeit drugs.
Issues related to compounding and counterfeit drugs.
Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JAPAN TOBACCO INTERNATIONAL USA INC. via S-3 GROUP
2026 · second_quarter · Q2
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
BROWN-FORMAN CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to corporate tax policy, tariffs, including duty drawbacks
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SWISHER INTERNATIONAL INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues pertaining to tobacco and nicotine; monitoring activity at FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to auto parts market
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to privacy, data security, and funding
Issues related to privacy, data security, and funding
Issues related to privacy and data security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding lower prescription drug prices for patients
Issues regarding lower prescription drug prices for patients
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Product applications related to the FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · second_quarter · Q2
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous platforms for border and national security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MONDELEZ INTERNATIONAL via S-3 GROUP
2026 · second_quarter · Q2
Issues related to food and nutrition policy
Issues related to trade, taxes, and tariffs
Issues related to trade, taxes, and tariffs
ABBOTT LABORATORIES via S-3 GROUP
2026 · second_quarter · Q2
Proposals to reform domestic and international tax structures
Equitable Access to Community Pharmacist Services Act
Equitable Access to Community Pharmacist Services Act
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL INSURANCE CRIME BUREAU via S-3 GROUP
2026 · second_quarter · 2T
Issues related to consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · second_quarter · Q2
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · second_quarter · Q2
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · second_quarter · Q2
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via S-3 GROUP
2026 · second_quarter · Q2
Issues related to funding for newborn screenings for metachromatic leukodystrophy
Issues related to funding for newborn screenings for metachromatic leukodystrophy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN EXPLORATION & PRODUCTION COUNCIL via S-3 GROUP
2026 · second_quarter · Q2
Monitor issues and legislation to support the resonsible production of American oil and gas
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCKET LIMITED PARTNERSHIP F/K/A RKT HOLDINGS, LLC via S-3 GROUP
2026 · second_quarter · Q2
General tax reform; qualified office conversion tax credit
Mortgage servicing and data privacy issues; general FHA, FHFA, VA, USDA issues; oversight of federal housing policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANDOZ INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues and legislative proposals on biosimilars and generics medicines, including but not limited to generics and biosimilar sustainability, pharmaceutical supply chain security, drug shortages, interchangeability, patent litigation, and PBM reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to policy matters impacting labor, independent workers, gig economy, consumer issues and food, restaurant, small businesses
Issues pertaining to policy matters impacting labor, independent workers, gig economy, consumer issues and food, restaurant, small businesses
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Monitor issues related to consumer data privacy, and children's privacy
General educational meetings on policy issues impacting tech platforms
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
S. 448/H.R. 4128 (CIRCUIT Act), and future opportunities (Recon 3.0), focusing on expansion of the 45X tax credit
H.R. 4194 Limiting Liability for Critical Infrastructure Manufacturers Act (Wildfire liability protections for manufacturers of critical grid components)
Section 232 tariffs, including measures affecting steel, aluminum, semiconductors, and critical minerals, as well as actions related to reciprocal tariffs; advanced NEMA's tariff incentive proposal to accelerate energy and domestic manufacturing priorities.
2026 · second_quarter · Q2
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
Issued related to PL 119-21: One Big Beautiful Bill Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FORIS DAX, INC. D/B/A CRYPTO.COM via S-3 GROUP
2026 · second_quarter · Q2
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Advocating on behalf of users of cryptocurrency and the process of how consumers invest, save, trade, in the digital place
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
META PLATFORMS, INC. (FORMERLY FACEBOOK, INC. AND VARIOUS SUBSIDIARIES) via S-3 GROUP
2026 · second_quarter · Q2
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER BRANDS ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to the food and beverage industries
Issues related to the food and beverage industries
Consumer packaged goods and sustainability and recyclability of packaged goods
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities; issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE CLIENT SERVICES, LLC via S-3 GROUP
2026 · second_quarter · Q2
Issues related to human trafficking efforts and criminal justice reform
Issues related to intellectual property enforcement
Issues related to funding in Appropriations bills and internet governance
RECYCLING LEADERSHIP COUNCIL via S-3 GROUP
2026 · first_quarter · Q1
Issues pertaining to advanced recycling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.
Issues related to tariffs and importation of counterfeit drugs.
Issues related to compounding and counterfeit drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JAPAN TOBACCO INTERNATIONAL USA INC. via S-3 GROUP
2026 · first_quarter · Q1
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
BROWN-FORMAN CORPORATION via S-3 GROUP
2026 · first_quarter · Q1
Issues related to proposed FDA dietary guidelines for alcohol
Issues related to corporate tax policy, tariffs, including duty drawbacks
Issues related to corporate tax policy, tariffs, including duty drawbacks
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SWISHER INTERNATIONAL INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues pertaining to tobacco and nicotine; monitoring activity at FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to auto parts market
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to privacy and data security
Issues related to privacy, data security, and funding
Issues related to privacy, data security, and funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding lower prescription drug prices for patients
Issues regarding lower prescription drug prices for patients
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNC FINANCIAL INC. via S-3 GROUP
2026 · first_quarter · Q1
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Product applications related to the FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · first_quarter · Q1
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous platforms for border and national security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to trade
Issues related to privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MONDELEZ INTERNATIONAL via S-3 GROUP
2026 · first_quarter · Q1
Issues related to trade, taxes, and tariffs
Issues related to trade, taxes, and tariffs
Issues related to food and nutrition policy
ABBOTT LABORATORIES via S-3 GROUP
2026 · first_quarter · Q1
Equitable Access to Community Pharmacist Services Act
Equitable Access to Community Pharmacist Services Act
Proposals to reform domestic and international tax structures
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2026 · first_quarter · Q1
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL INSURANCE CRIME BUREAU via S-3 GROUP
2026 · first_quarter · Q1
Issues related to consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · first_quarter · Q1
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · first_quarter · Q1
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · first_quarter · Q1
Issues related to pharmacy, pharmacist provider status, and Medicare reimbursement
Issues related to the provider status of pharmacists under Medicare Part B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · first_quarter · Q1
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · first_quarter · Q1
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via S-3 GROUP
2026 · first_quarter · Q1
Issues related to funding for newborn screenings for metachromatic leukodystrophy
Issues related to funding for newborn screenings for metachromatic leukodystrophy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN EXPLORATION & PRODUCTION COUNCIL via S-3 GROUP
2026 · first_quarter · Q1
Monitor issues and legislation to support the resonsible production of American oil and gas
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitor trade, tax issues and regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to trade, taxes, and tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Equitable Access to Community Pharmacist Services Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the food and beverage industries
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding in Appropriations bills and internet governance
Issues related to privacy and data security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitor trade, tax issues and regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to food and nutrition policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to infant formula
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 4105 (Veterans Energy Transition Act)
Electrification policy; energy efficiency; grid and cyber security; transmissions; permitting reform; HR. 6633 High Capacity Grid Act alongside REWIRE Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the food and beverage industries
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to competition in online services
Issues related to privacy and data security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitor trade, tax issues and regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to food and nutrition policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to infant formula
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE